Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Holy Stone Healthcare Co. Ltd. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. Both of these actions are assigned to 1 distinct examiner and 1 distinct art unit. This indicates a concentration for the company's current prosecution, with all active matters being reviewed by the same individual. Such a setup can lead to consistent feedback across the applications but also makes the portfolio's success dependent on a single relationship.
OLSON, ANDREA STEFFEL is the busiest examiner, managing 2 busiest_examiner_pending actions. Because there are 2 pending office actions in total, this single examiner is responsible for the entire active workload. The fact that both actions are in 1 distinct art unit suggests that the applications involve related biotechnological subject matter. Practitioners should focus on building a cohesive narrative with this examiner, as their interpretation of the 1 distinct art unit's guidelines will be the deciding factor for all currently pending matters. This centralized environment allows for a unified prosecution strategy across the active portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OLSON, ANDREA STEFFEL | 2 | 62.4% | -11.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18740235 | METHODS OF USING COMPOUND OF GLYCOSAMINOGLYCAN | OLSON, ANDREA STEFFEL | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18740235 | METHODS OF USING COMPOUND OF GLYCOSAMINOGLYCAN | OLSON, ANDREA STEFFEL | — | §102§103§112Other | Non-Final OA | — | Pending | Jun 11, 2024 |
| 14469028 | COMPOUND OF GLYCOSAMINOGLYCAN AND ITS PREPARATION METHOD AS WELL AS APPLICATION | OLSON, ANDREA STEFFEL | 1693 | §103 | Final Rejection | — | Pending | Aug 26, 2014 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHoly Stone Healthcare Co. Ltd. has 2 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Andrea Steffel Olson has the most, with 2 of Holy Stone Healthcare Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
